v3.26.1
SEGMENT INFORMATION - Schedule of Reportable Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Total revenues $ 989,708 $ 825,410 $ 1,755,916 $ 1,570,555
Cost of sales 202,795 150,090 397,794 301,648
R&D expenses 206,952 161,308 385,748 320,039
NET INCOME 44,762 240,532 150,289 426,218
Reportable Segment        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Total revenues 989,708 825,410 1,755,916 1,570,555
Cost of sales 202,795 150,090 397,794 301,648
S&M expenses 142,186 122,100 267,113 224,631
G&A expenses 253,363 110,179 386,726 213,764
Other segment expense, net 139,650 41,201 168,246 84,255
NET INCOME 44,762 240,532 150,289 426,218
Research and early pipeline | Reportable Segment        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
R&D expenses 85,069 95,968 172,360 186,438
Later-stage clinical programs | Reportable Segment        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
R&D expenses 50,295 13,133 86,472 27,424
Marketed products | Reportable Segment        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
R&D expenses $ 71,588 $ 52,207 $ 126,916 $ 106,177